ABBVIE INC

AbbVie expands its EU portfolio with RINVOQ’s new pediatric arthritis indication while launching the patient‑centric AA Signature™: SKIN360 aesthetic bundle, blending clinical innovation, reimbursement strategy, and operational efficiency for high‑g…

AbbVie partners with AI drug‑developer Iambic to accelerate oncology and neuroscience discoveries, cut timelines, boost market‑access and aim for >$3 billion ROI.

AbbVie’s steady stock, robust dividends, and portfolio expansion strategy show how the biopharma leader balances growth and risk in a volatile market.

AbbVie expands its philanthropic reach with “Birdies for Brain Health,” boosts scientific leadership via exosome‑based skincare, and reaffirms commitment to immunology, neuroscience, and oncology.

AbbVie’s 2026 AGM: governance changes, new incentive plan, audited financials, and insights on Humira, Venclexta, bispecifics and future growth.

AbbVie’s latest $1.73 dividend hike showcases strong cash flow, value‑based pricing, and strategic R&D—insights that boost shareholder value and future growth.

AbbVie’s dividend growth and $1.73/share payout, coupled with breakthrough atogepant migraine results and a diversified pipeline, promise shareholder value and future growth.

AbbVie keeps dividends rising while fueling drug‑pipeline growth, balancing strong cash flow, R&D investment, and value‑based reimbursement to boost shareholder returns and patient access.

How AbbVie’s dividend, CDMO growth, and gene‑therapy deals prepare it for Humira’s patent cliff and a shifting biotech market.

AbbVie’s Phase‑3 win for bispecific drug etentamig and $10.9bn Apogee acquisition boost oncology, dermatology, and asthma portfolios—driving future growth and value‑based pricing.